logo
Bondi attacker's psychiatrist backflips over ‘woman hater' claim

Bondi attacker's psychiatrist backflips over ‘woman hater' claim

'I don't have evidence, it was conjecture on my part and I shouldn't have said that,' Dr A said.
'I shouldn't have speculated all the years later after I completed his treatment.'
Within months of ceasing his antipsychotics in 2019, Cauchi's mother Michele began raising the alarm with Dr A's clinic about her son's strange behaviour. She made seven attempts to raise concerns, according to clinical notes.
The inquest has heard Cauchi was scrawling countless messages about 'Satanic control', obsessed with pornography and showering compulsively.
His mother felt he was hearing voices, but Dr A has consistently denied they were warning signs of psychosis.
'Is hearing voices a sign of psychosis?' Chrysanthou asked.
'Yes, if it was evidenced, but there was no evidence … She didn't even live with him, it's just an opinion of the mother,' Dr A said.
Cauchi was ultimately discharged from the private clinic in 2020 at the same time he moved to Brisbane.
Dr A had one final telehealth session with Cauchi, but it was cancelled because he had tech issues with Skype and Medicare would not cover the session.
'The government removed the rebate from the telehealth appointment. I'm a private psychiatrist,' Dr A told the court.
The psychiatrist said she desperately wanted to keep Cauchi in her care, and wanted him to return to her clinic.
But, unless he was a risk to himself or others, she could not invoke the public health act to forcibly medicate him.
The powers, or lack thereof, of the mental health act in Queensland will be key to the inquest's findings, with both police and medical professionals unable to force Cauchi into care.
'My responsibility is not to medicate the person that doesn't have psychosis,' Dr A told the court.
Cauchi floated in and out of Toowoomba, where his parents lived, but enrolled with a new medical centre in Brisbane. That medical centre requested the 'medical summary' and 'all clinical notes' from Dr A, but she did not pass them on.
Chrysanthou said it was 'a failing' on Dr A's part. The new doctors did not know she felt Cauchi needed monthly monitoring. They also did not know about the concerns raised in the months prior.
'What was the use of a new doctor who didn't know his 20-year history because you didn't hand over the notes?' Chrysanthou asked.
Dr A said she handed over four recent documents and letters, which was standard practice.
'If they wanted to have anything more they can call me, they can ring me,' Dr A said.
Loading
'We don't send patients' clinical notes with private psychiatrists. They have to specifically ask for the whole file to be transferred. Nobody wants the whole file to be transferred … This is [accepted] within psychiatric circles. Some psychiatrists just give the last letter.'
Dr A, at the end of her evidence on Wednesday, broke down in tears and was comforted in the witness box by her lawyer.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Health Check: Whether stoic or simply too poor, Australians spurn GP visits
Health Check: Whether stoic or simply too poor, Australians spurn GP visits

News.com.au

time04-06-2025

  • News.com.au

Health Check: Whether stoic or simply too poor, Australians spurn GP visits

Doctor visits dipped in April, reversing a recovery trend Mayne Pharma threatens to go legal in takeover dispute … but peace erupts at Cann Group with settlement of legal spat We're either a healthy lot, rely on Dr Google or simply can't afford to visit a GP anymore. Take your pick as to why our doctor visitations are running below the historic trend. Medicare data for April shows a resumption of a decline in doctors' visits, thus reversing a recent recovery. Bell Potter says the 12-month rolling rate slipped back to 0.8% from 2.3% in March and now is below the long-term median 1.4% growth. In April last year, the rolling rate had dipped to -3%. The slippage was most apparent in Queensland, which shows what stoic souls they are up north. Or maybe they couldn't get to their clinics because they were hemmed in by floods. The rate of doctors' visits has a direct impact on diagnostic imaging volumes and thus is relevant for stocks such as Sonic Healthcare (ASX:SHL), Integral Diagnostics (ASX:IDX), Healius (ASX:HLS) and Australian Clinical Labs (ASX:ACL). (Healius sold its 69 medical centres to private equity firm BGH Capital for $500 million in November 2020.) Macquarie Equities says both pathology and imaging volumes grew 4% in April, year on year. But the DI providers look to be protected by more expensive procedures – 'higher fee modalities', as the firm puts it – with benefits paid rising 8% in April for pathology and 7% for imaging. On the bright side, face-to-face GP visits have held up relative to telehealth and the former is likely to result in diagnostic referrals. So it's a bit of a mixed picture. The re-elected Albo's pledge to extend bulk billing might also ramp up volumes. What will restrain the pain at Mayne? Mayne Pharma's (ASX:MYX) takeover is in the balance, with a 10-day consultation period expiring without suitor Cosette Pharmaceuticals pulling the plug. Cosette alleged that events had resulted in a 'material adverse change', thus triggering the consultation period. Mayne denies these events were material. The FDA has accused Mayne Pharma of downplaying the risks of its oral birth control pill, Nextstellis. Mayne Pharma now says the agency is satisfied the company has addressed the identified issues. Mayne is also in a tat-for-tat legal dispute with the Nasdaq-listed Therapeutics MD, relating to Mayne's purchase of assets from the latter in 2022. While Cosette is yet to walk, the terms of the scheme implementation deed (SID) enable the suitor to do so any time up to the second court hearing to approve the deal. The affair may end up in the courts in a different way, given Mayne 'intends to take all reasonable steps to enforce its rights under the SID.' This includes litigation, of course. Mayne shares this morning surged 5%, but they remain 32% below Cosette's $7.40 a share cash offer. So investors are saying the deal might have a pulse, but not at the original offer price. Cann Group pots legal settlement Medical cannabis play Cann Group (ASX:CAN) has settled a legal dispute with the NZ-listed Rua Biosciences, which had sued a Cann subsidiary over a manufacturing and supply agreement. As is the norm, the agreement is confidential but doesn't involve any money changing hands. Instead, the parties have agreed that Cann will supply 'certain medicinal cannabis products' to Rua under 'agreed market standard commercial terms.' As far as legal spats go, it sounds like a reasonable result. Across the Tasman, Rua shares were up more than 7% this morning Cann shares were about 3% off the pace, having lost 65% of their value year to date. The first Australian company to receive an Australian cannabis research and cultivation licence, Cann produces from its modern Mildura facility. But in the current oversupplied market, it's not easy being green. Radiopharm tackles HER-2 cancers Radiopharm Theranostics (ASX:RAD) has dosed the first patient in its phase I trial to treat advanced HER2-positive solid tumours. A human epidermal growth factor receptor, HER2 is expressed in a variety of tumours including some breast cancers. Dubbed Heat, the study road tests Radiopharm's lutetium isotope-based therapy. Taking place at multiple local centres, the study has the usual safety and tolerability remits. It also aims for the optimal dosage for a phase II trial, as well as early efficacy signals. 'Despite progressive improvements in the management of metastatic HER2-positive disease, the majority of patients experience disease progression on current standard of care and require further therapeutic options,' Radiopharm CEO Riccardo Canevari says. On Monday, the company said preclinical data from another program showed 'favorable biodistribution and ... maintained tumor uptake.' This one refers to its lutetium-based monoclonal antibody RV01, which targets solid tumours expressing the B7H3 protein. This one is via a joint venture with Houston's MD Anderson Cancer Center to develop at least four radiopharmaceutical products. The next step is FDA assent to run a first-in-human trial, which the company hopes to kick off in 2026.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store